We are live on ! Find out more
FCMV

Foresite Capital Management VI Portfolio holdings

AUM $460M
1-Year Est. Return 261.77%
This Fund
S&P 500
This Quarter Est. Return
+81.53%
1 Year Est. Return
+261.77%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$259M
AUM Growth
+$81M
Cap. Flow
-$11.9M
Cap. Flow %
-4.61%
Top 10 Hldgs %
98.7%
Holding
21
New
1
Increased
3
Reduced
–
Closed
9

Top Buys

Rank Stock Value
1
DNLI icon
Denali Therapeutics
DNLI
+$14.4M
2
VSTM icon
Verastem
VSTM
+$9.96M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$1.08M
4
CASI
CASI Pharmaceuticals
CASI
+$344K

Top Sells

Rank Stock Value
1
BCAX
Bicara Therapeutics
BCAX
+$8.82M
2
EWTX icon
Edgewise Therapeutics
EWTX
+$7.67M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$5.01M
4
CGEM icon
Cullinan Oncology
CGEM
+$4.47M
5
GPCR icon
Structure Therapeutics
GPCR
+$4.36M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGON icon
1
CG Oncology
CGON
$6.32B
$89.5M 34.57%
2,221,474
– –
RAPT
2
DELISTED
RAPT Therapeutics
RAPT
$40.3M 15.57%
1,562,500
– –
CNTA
3
DELISTED
Centessa Pharmaceuticals
CNTA
$31.9M 12.31%
1,314,019
+60,640
+5% +$1.08M
VSTM icon
4
Verastem
VSTM
$541M
$23.1M 8.92%
2,615,120
+1,338,600
+105% +$9.96M
ALMS
5
Alumis Inc
ALMS
$3.42B
$16.9M 6.55%
4,247,670
– –
DNLI icon
6
Denali Therapeutics
DNLI
$3.76B
$14.5M 5.61%
+1,000,000
New +$14.4M
CRVS icon
7
Corvus Pharmaceuticals
CRVS
$1.1B
$12.8M 4.93%
1,731,233
– –
AKRO
8
DELISTED
Akero Therapeutics
AKRO
$11.6M 4.49%
244,900
– –
KYMR icon
9
Kymera Therapeutics
KYMR
$8.75B
$8.28M 3.2%
146,332
– –
HNGE
10
Hinge Health
HNGE
$5.82B
$6.63M 2.56%
135,000
– –
RNAM
11
DELISTED
Avidity Biosciences
RNAM
$1.74M 0.67%
40,000
– –
CASI
12
DELISTED
CASI Pharmaceuticals
CASI
$1.63M 0.63%
979,956
+192,835
+24% +$344K
ALLO icon
13
Allogene Therapeutics
ALLO
$563M
– –
-2,875,357
Closed -$3.25M
CGEM icon
14
Cullinan Oncology
CGEM
$1.08B
– –
-594,025
Closed -$4.47M
EWTX icon
15
Edgewise Therapeutics
EWTX
$4.37B
– –
-585,000
Closed -$7.67M
GPCR icon
16
Structure Therapeutics
GPCR
$3.37B
– –
-210,000
Closed -$4.36M
IDYA icon
17
IDEAYA Biosciences
IDYA
$3.45B
– –
-144,468
Closed -$3.04M
SYRE icon
18
Spyre Therapeutics
SYRE
$8.47B
– –
-70,000
Closed -$1.05M
VRDN icon
19
Viridian Therapeutics
VRDN
$2.14B
– –
-1,974
Closed -$27.6K
XENE icon
20
Xenon Pharmaceuticals
XENE
$6.29B
– –
-160,000
Closed -$5.01M
BCAX
21
Bicara Therapeutics
BCAX
$1.76B
– –
-949,260
Closed -$8.82M

Similar funds

MCB
Morton Community Bank East Peoria, Illinois $460M AUM 17.72% 1-Year Est. Return
WCM
Weaver Capital Management Suwanee, Georgia $461M AUM 20.77% 1-Year Est. Return
PC
Pureheart Capital Singapore $459M AUM 23.59% 1-Year Est. Return
PIN
Prudent Investors Network Lake Forest, California $459M AUM 9.48% 1-Year Est. Return
FCG
Fielder Capital Group Nashville, Tennessee $459M AUM 48.94% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return
PRCP
Pacific Ridge Capital Partners Lake Oswego, Oregon $462M AUM 40.76% 1-Year Est. Return
AC
Aristides Capital Louisville, Kentucky $462M AUM 28.94% 1-Year Est. Return

Foresite Capital Management VI's Q3 2025 Portfolio in Review

As of Q3 2025, Foresite Capital Management VI held 21 positions worth $259M, up 46% from $178M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Foresite Capital Management VI withdrew a net $11.9M in Q3 2025, closing 9 positions. Its most notable exit was Bicara Therapeutics, an estimated $8.82M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Foresite Capital Management VI opened a new position in Denali Therapeutics worth $14.5M.

  • Foresite Capital Management VI's largest Q3 2025 buy was Denali Therapeutics: 1,000,000 shares worth $14.5M.
  • Foresite Capital Management VI added most to Verastem in Q3 2025, an estimated $9.96M increase.
  • Foresite Capital Management VI fully exited Bicara Therapeutics in Q3 2025, selling an estimated $8.82M.
  • Foresite Capital Management VI's ten largest holdings make up 99% of its $259M portfolio in Q3 2025.
  • Foresite Capital Management VI opened 1 new position and closed 9 in Q3 2025.
  • Foresite Capital Management VI's portfolio value rose 46% quarter-over-quarter to $259M.

Based on Foresite Capital Management VI's 13F filing for Q3 2025, filed 14 Nov 2025.